Virginia Commonwealth University
vcu.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
641
Active
97
Phase 3
28
Total enrollment
22,833,461
Pipeline matrix
Showing 40 of 40 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Galantamine HBr extended-release 8mg capsules (8mg ER). | — | — | — | — | — | 1 | |
| Oral Azacitidine | — | — | — | — | — | 1 | |
| Letermovir 480 mg once daily | — | — | — | — | — | 1 | |
| Anakinra | — | — | 14 | ||||
| Cyclophosphamide | — | — | — | — | 2 | ||
| Paclitaxel | — | — | — | — | 2 | ||
| carboplatin | — | — | — | — | 2 | ||
| Doxorubicin | — | — | — | — | 2 | ||
| Pembrolizumab | — | — | — | — | — | 2 | |
| Carvedilol | — | — | — | — | — | 2 | |
| Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin | — | — | — | — | — | 1 | |
| Sacituzumab Tirumotecan | — | — | — | — | — | 1 | |
| Decitabine | — | — | — | — | — | 1 | |
| Valbenazine | — | — | — | — | — | 1 | |
| Accelerated partial breast irradiation | — | — | — | — | — | 1 | |
| Intestinal Microbiota Transplant (IMT) | — | — | — | — | — | 1 | |
| Partial Breast Irradiation | — | — | — | — | — | 1 | |
| Reduced Dose of Chemotherapy and Immunotherapy | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Rotigotine Transdermal System [Neupro] | — | — | — | — | — | 1 | |
| Lemborexant 10 MG | — | — | — | — | — | 1 | |
| Sacubitril-valsartan | — | — | — | — | — | 1 | |
| Valsartan | — | — | — | — | — | 1 | |
| Zanubrutinib | — | — | — | — | — | 1 | |
| Olutasidenib Investigational Agent Administration | — | — | — | — | — | 1 | |
| Azelaic Acid | — | — | — | — | — | 1 | |
| Low-dose colchicine at 0.5mg daily | — | — | — | — | — | 1 | |
| Neratinib 160 mg | — | — | — | — | — | 1 | |
| Neratinib 200 mg | — | — | — | — | — | 1 | |
| Neratinib 240 mg | — | — | — | — | — | 1 | |
| Niraparib 100 mg | — | — | — | — | — | 1 | |
| Niraparib 200 mg | — | — | — | — | — | 1 | |
| Niraparib 300 mg | — | — | — | — | — | 1 | |
| Niraparib at RP2D | — | — | — | — | — | 1 | |
| Neratinib at RP2D | — | — | — | — | — | 1 | |
| VVZ-2471 for 14-day intervention | — | — | — | — | — | 1 | |
| Arm 1 cemiplimab | — | — | — | — | — | 1 | |
| Arm 2 cemiplimab and fianlimab | — | — | — | — | — | 1 | |
| Investigational Agent Administration | — | — | — | — | — | 1 | |
| Blood draw | — | — | — | — | — | 1 |
Next readouts
- 2022-08-04
- 2024-10-30
- 2026-06
- 2026-07
- 2026-08
- 2026-08-30
- 2026-09-01
- 2027-01-31
- 2027-02-22
- 2027-04-30
Top conditions
- Obesity22
- Breast Cancer21
- Leukemia12
- Prostate Cancer10
- Pediatric Obesity9
- Stress9
- Traumatic Brain Injury9
- Lymphoma9
Frequently asked questions about Virginia Commonwealth University
- How many clinical trials does Virginia Commonwealth University have on ClinicalTrials.gov?
- Virginia Commonwealth University is listed as the lead sponsor on 641 clinical trials in ClinicalTrials.gov, 97 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Virginia Commonwealth University's trials are in Phase 3?
- 28 of Virginia Commonwealth University's trials are in Phase 3, spread across 40 active drug programs.
- What therapeutic areas does Virginia Commonwealth University focus on?
- Virginia Commonwealth University's most-studied conditions on ClinicalTrials.gov are Obesity, Breast Cancer, Leukemia, Prostate Cancer, Pediatric Obesity.
- When are Virginia Commonwealth University's next clinical trial readouts?
- Virginia Commonwealth University has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca”, expected around 2022-08-04.